Unraveling the Mysteries of Science and Disease
From: The Jerusalem Post
Weizmann Prof. Emeritus Michel Revel’s long, brilliant career includes co-developing Copaxone® and Rebif®, two of the world’s leading MS drugs. At 75, rather than retire, he’s still breaking ground: his new biotech firm is developing applications for human embryonic stem cells, aiming to better treat – and cure – diabetes and other diseases.
February 23, 2014